Lyndra Therapeutics

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Lyndra Therapeutics is making daily pills a thing of the past. Instead of trying to change the patient to improve adherence, Lyndra is changing the pill.

Medication non-adherence is a $289 billion problem in the U.S. alone. Instead of having to take medications daily or more frequently, Lyndra’s oral, ultra-long-acting, sustained-release therapies, could allow patients to take medication weekly, or even monthly This would improve medication adherence and health outcomes and help lower the cost of care.

Lyndra’s near-term focus is on addressing health conditions where therapeutic need is largely unmet and where patient non-adherence has been well documented to adversely affect health outcomes.
The current pipeline includes therapies for Alzheimer’s disease, HIV, opioid use disorder and schizophrenia as well as a new once-monthly option for oral contraception.
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
Risperidone
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Lyndra Therapeutics